资讯

Fierce Pharma8 小时
Fierce Pharma Asia—Pfizer's PD-1xVEGF bet; An Alzheimer's blood test approval; Samsung's ...
Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...
AzerNews18 小时
Samsung Biologics plans to set up holding company to separate CDMO, biosimilar biz
Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it plans to spin off its ...
Samsung Biologics plans to separate CDMO, biosimilar biz
Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...